Search research articles
Contact Us
Filters
Showing results (31-40 of 89) with videos related to
Page
of 9
Sort By:
Journal of Experimental & Clinical Cancer Research : CR
|
June 23, 2017
MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells
Zhong Zheng, Peng-Peng Xu, Li Wang, et al.
Signal Transduction and Targeted Therapy
|
January 12, 2021
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis
Yao-Hui Huang, Kun Cai, Peng-Peng Xu, et al.
Molecular Cancer
|
July 11, 2026
TBL1XR1 mutations promoted tumor progression in diffuse large B-cell lymphoma through impairing nature killer cytotoxicity via the MYC-CD47/PD-L1 axis
Yue Zhu, Yi-Ge Shen, Wei Tang, et al.
Cell Reports. Medicine
|
February 13, 2024
Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes
Yao-Hui Huang, Yu-Ran Qiu, Qun-Ling Zhang, et al.
The Lancet Regional Health. Western Pacific
|
August 23, 2024
Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial
Ming-Ci Cai, Shu Cheng, Hong-Mei Jing, et al.
The Lancet. Healthy Longevity
|
September 14, 2022
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study
Peng-Peng Xu, Zi-Yang Shi, Ying Qian, et al.
Ebiomedicine
|
October 10, 2021
SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential
Jie Xiong, Nan Wang, Hui-Juan Zhong, et al.
Cancer Communications (London, England)
|
July 5, 2023
Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial
Qing Shi, Yang He, Hong-Mei Yi, et al.
Blood Cancer Discovery
|
June 24, 2026
Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphoma
Jiahao Chen, Xiao-Yu Wu, Xiang Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 25, 2019
Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
Zi-Xun Yan, Li Li, Wen Wang, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 89) with videos related to
Sort By:
Page
of 9
Journal of Experimental & Clinical Cancer Research : CR
|
June 23, 2017
MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells
Zhong Zheng, Peng-Peng Xu, Li Wang, et al.
Signal Transduction and Targeted Therapy
|
January 12, 2021
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis
Yao-Hui Huang, Kun Cai, Peng-Peng Xu, et al.
Molecular Cancer
|
July 11, 2026
TBL1XR1 mutations promoted tumor progression in diffuse large B-cell lymphoma through impairing nature killer cytotoxicity via the MYC-CD47/PD-L1 axis
Yue Zhu, Yi-Ge Shen, Wei Tang, et al.
Cell Reports. Medicine
|
February 13, 2024
Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes
Yao-Hui Huang, Yu-Ran Qiu, Qun-Ling Zhang, et al.
The Lancet Regional Health. Western Pacific
|
August 23, 2024
Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial
Ming-Ci Cai, Shu Cheng, Hong-Mei Jing, et al.
The Lancet. Healthy Longevity
|
September 14, 2022
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study
Peng-Peng Xu, Zi-Yang Shi, Ying Qian, et al.
Ebiomedicine
|
October 10, 2021
SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential
Jie Xiong, Nan Wang, Hui-Juan Zhong, et al.
Cancer Communications (London, England)
|
July 5, 2023
Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial
Qing Shi, Yang He, Hong-Mei Yi, et al.
Blood Cancer Discovery
|
June 24, 2026
Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphoma
Jiahao Chen, Xiao-Yu Wu, Xiang Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 25, 2019
Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
Zi-Xun Yan, Li Li, Wen Wang, et al.
Page
of 9